Clinical trial
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
NCT00337610 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00337610 |
|---|---|
| Title | Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus |
| Official title | A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus (T2DM) |
| Intervention type | Drug |
| Interventions | sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day, comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day |
| Enrollment | 190 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jun 16, 2006 |
| Last update posted | May 12, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: